OncoSec Medical Inc (ONCSQ)

[hschlauch]

Thanks for sharing. CTLA-4 is constitutively expressed on FOXP3-positive Tregs as well. We know CTLA-4 has a greater affinity to CD80 and CD86 on dendritic cells than CD28. In fact, there is evidence of CTLA-4 physically removing CD80 and CD86 on dendritic cells, thus leaving them completely unable to interact with CD28 on CD8 T cells. This ultimately prevents activation/stimulation of immune responses specific to the antigens presented by dendritic cells. CTLA-4 hijacks antigen presentation and they mostly do it in the tumor microenvironment and tumor draining lymph nodes.